Soligenix Inc. Announces Positive Phase 2a Study Results for SGX945 in Behçet’s Disease Treatment

Soligenix Inc. (NASDAQ: SNGX) has recently unveiled encouraging results from its Phase 2a proof of concept study for SGX945 (dusquetide), targeting Behçet’s Disease. The study demonstrated a 40% improvement in the ulcer endpoint when compared to a historical placebo group from the apremilast (Otezla(R)) Phase 3 study, marking a significant milestone in the treatment of this rare disease. Remarkably, the benefits were sustained even after treatment was discontinued at four weeks, with seven out of eight participants experiencing reductions in ulcer duration, number, and pain, all without any treatment-related adverse events.

Christopher J. Schaber, CEO of Soligenix, emphasized the importance of these findings, noting their potential to accelerate the development of SGX945. The company is now focusing on reformulating the drug for home-based subcutaneous administration, which could significantly enhance its accessibility and applicability for Behçet’s Disease and other innate immune-related inflammatory conditions. This advancement is particularly critical given the scarcity of effective treatments for Behçet’s Disease, a chronic condition characterized by widespread vascular inflammation.

The positive outcomes from the SGX945 study not only underscore the drug's potential as a novel therapeutic option but also highlight Soligenix's commitment to addressing unmet medical needs in rare diseases. For further information on Soligenix's research and development efforts, visit https://www.Soligenix.com. Additional updates and insights into Soligenix's progress can be found at https://ibn.fm/SNGX.